{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:23:59Z","timestamp":1791343439081,"version":"4.3.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this study, we have addressed how Lyn kinase signaling mediates nilotinib-resistance by quantitative phospho-proteomics using Stable Isotope Labeling with Amino acid in Cell culture. We have found an increased tyrosine phosphorylation of 2 additional tyrosine kinases in nilotinib-resistant cells: the spleen tyrosine kinase Syk and the UFO family receptor tyrosine kinase Axl. This increased tyrosine phosphorylation involved an interaction of these tyrosine kinases with Lyn. Inhibition of Syk by the inhibitors R406 or BAY 61-3606 or by RNA interference restored the capacity of nilotinib to inhibit cell proliferation. Conversely, coexpression of Lyn and Syk were required to fully induce resistance to nilotinib in drug-sensitive cells. Surprisingly, the knockdown of Syk also strongly decreased tyrosine phosphorylation of Lyn and Axl, thus uncovering interplay between Syk and Lyn. We have shown the involvement of the adaptor protein CDCP-1 in resistance to nilotinib. Interestingly, the expression of Axl and CDCP1 were found increased both in a nilotinib-resistant cell line and in nilotinib-resistant CML patients. We conclude that an oncogenic signaling mediated by Lyn and Syk can bypass the need of Bcr-Abl in CML cells. Thus, targeting these kinases may be of therapeutic value to override imatinib or nilotinib resistance in CML.<\/jats:p>","DOI":"10.1182\/blood-2010-10-313692","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T00:56:19Z","timestamp":1309913779000},"page":"2211-2221","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells"],"prefix":"10.1182","volume":"118","author":[{"given":"Romain","family":"Gioia","sequence":"first","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Leroy","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique UMR5237, Centre de Recherche de Biochimie Macromol\u00e9culaire, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Drullion","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lagarde","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Etienne","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dulucq","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Roche","sequence":"additional","affiliation":[{"name":"Centre National de la Recherche Scientifique UMR5237, Centre de Recherche de Biochimie Macromol\u00e9culaire, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Max","family":"Pasquet","sequence":"additional","affiliation":[{"name":"H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cible Th\u00e9rapeutique, Inserm U1035, Universit\u00e9 Victor S\u00e9galen, Bordeaux, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111807455612800_B1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0065-230X(08)60423-6","article-title":"Chromosome abnormalities in malignant hematologic diseases.","volume":"36","author":"Rowley","year":"1982","journal-title":"Adv Cancer Res"},{"issue":"Pt 2","key":"2019111807455612800_B2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1101\/SQB.1986.051.01.104","article-title":"Oncogene activation by chromosomal translocation in chronic myelocytic leukemia.","volume":"51","author":"Groffen","year":"1986","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"7","key":"2019111807455612800_B3","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"issue":"4944","key":"2019111807455612800_B4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"4946","key":"2019111807455612800_B5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"issue":"3","key":"2019111807455612800_B6","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1074\/jbc.M209677200","article-title":"BMS-345541 is a highly selective inhibitor of I[kappa]B kinase that binds at an allosteric site of the enzyme and blocks NF-[kappa]B-dependent transcription in mice.","volume":"278","author":"Burke","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111807455612800_B7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"issue":"23","key":"2019111807455612800_B8","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"2019111807455612800_B9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111807455612800_B10","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1158\/0008-5472.CAN-08-2354","article-title":"Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells.","volume":"69","author":"Leroy","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"2019111807455612800_B11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.mt.6300030","article-title":"Murine Retroviral but not Human Cellular Promoters Induce In Vivo Erythroid-specific Deregulation that can be Partially Prevented by Insulators.","volume":"15","author":"Robert-Richard","year":"2007","journal-title":"Mole Ther"},{"issue":"23","key":"2019111807455612800_B12","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1158\/0008-5472.CAN-05-1270","article-title":"The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.","volume":"65","author":"Zyss","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"2019111807455612800_B13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.leu.2404463","article-title":"Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.","volume":"21","author":"Pocaly","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"2019111807455612800_B14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.febslet.2007.02.025","article-title":"Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells.","volume":"581","author":"Perry","year":"2007","journal-title":"FEBS Lett"},{"issue":"12","key":"2019111807455612800_B15","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2019111807455612800_B16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation.","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"2019111807455612800_B17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111807455612800_B18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.jbchem.a002970","article-title":"Structure and function of Syk protein-tyrosine kinase.","volume":"130","author":"Sada","year":"2001","journal-title":"J Biochem"},{"issue":"20","key":"2019111807455612800_B19","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1158\/0008-5472.CAN-03-3520","article-title":"Progressive loss of Syk and abnormal proliferation in breast cancer cells.","volume":"64","author":"Moroni","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"2019111807455612800_B20","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-08-2690","article-title":"Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.","volume":"69","author":"Bailet","year":"2009","journal-title":"Cancer Res"},{"issue":"30","key":"2019111807455612800_B21","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1038\/sj.onc.1204515","article-title":"Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.","volume":"20","author":"Goodman","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"2019111807455612800_B22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","article-title":"Proteomic and genetic approaches identify Syk as an AML target.","volume":"16","author":"Hahn","year":"2009","journal-title":"Cancer Cell"},{"issue":"7","key":"2019111807455612800_B23","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.","volume":"111","author":"Wu","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111807455612800_B24","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1128\/MCB.11.10.5016","article-title":"axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.","volume":"11","author":"O'Bryan","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2019111807455612800_B25","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V84.6.1931.1931","article-title":"Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis.","volume":"84","author":"Neubauer","year":"1994","journal-title":"Blood"},{"issue":"8","key":"2019111807455612800_B26","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1128\/MCB.17.8.4442","article-title":"Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts.","volume":"17","author":"Goruppi","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"22","key":"2019111807455612800_B27","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1038\/sj.onc.1201123","article-title":"Intracellular signaling of the Ufo\/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.","volume":"14","author":"Braunger","year":"1997","journal-title":"Oncogene"},{"issue":"48","key":"2019111807455612800_B28","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1038\/sj.onc.1208079","article-title":"The interplay between Src family kinases and receptor tyrosine kinases.","volume":"23","author":"Bromann","year":"2004","journal-title":"Oncogene"},{"issue":"40","key":"2019111807455612800_B29","doi-asserted-by":"crossref","first-page":"36940","DOI":"10.1074\/jbc.M204948200","article-title":"Activation of Syk Tyrosine Kinase Is Required for c-Cbl-mediated Ubiquitination of Fc\u03b5\u03bcRI and Syk in RBL Cells.","volume":"277","author":"Paolini","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111807455612800_B30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcp.20694","article-title":"The Cbl family proteins: Ring leaders in regulation of cell signaling.","volume":"209","author":"Swaminathan","year":"2006","journal-title":"J Cell Physiol"},{"issue":"3","key":"2019111807455612800_B31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2006-12-061176","article-title":"Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.","volume":"110","author":"Caligiuri","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111807455612800_B32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.110.066258","article-title":"Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.","volume":"78","author":"Zimmerman","year":"2010","journal-title":"Mol Pharm"},{"issue":"8","key":"2019111807455612800_B33","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1158\/0008-5472.CAN-06-3191","article-title":"Sulfasalazine Suppresses Drug Resistance and Invasiveness of Lung Adenocarcinoma Cells Expressing AXL.","volume":"67","author":"Lay","year":"2007","journal-title":"Cancer Res"},{"issue":"21","key":"2019111807455612800_B34","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.1128\/MCB.01246-07","article-title":"CDCP-1 is a novel regulator of anoikis resistance in lung adenocarcinoma.","volume":"27","author":"Uekita","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"6","key":"2019111807455612800_B35","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/0008-5472.CAN-07-2661","article-title":"AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression.","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"issue":"17","key":"2019111807455612800_B36","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL.","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res"},{"issue":"11","key":"2019111807455612800_B37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nm1127","article-title":"Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.","volume":"10","author":"Ptasznik","year":"2004","journal-title":"Nat Med"},{"issue":"13","key":"2019111807455612800_B38","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase.","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2211\/1349554\/zh803411002211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2211\/1349554\/zh803411002211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:58:21Z","timestamp":1574063901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/8\/2211\/29509\/Quantitative-phosphoproteomics-revealed-interplay"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-10-313692","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.12652957.13903055","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}